Technology Offerings

TLR2 Monoclonal Antibody: Targeting Immune Reactions

TLR2 represents an “earliest possible” target for prevention and therapeutic

intervention in the pathogenesis of harmful immune reactions whose blockage abrogates entry of the initial inflammatory signal into first-line defense host cells.

Further Information: PDF

Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000

Contact
Dr. Wolfgang Knappe

Comments (0)

Write a comment